Sensei Biotherapeutics Implements Reverse Stock Split
BOSTON — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a prominent clinical stage biotechnology company dedicated to advancing innovative treatments for cancer patients, has announced a strategic move to consolidate its common stock. This reverse stock split will occur on a 1-for-20 basis, officially taking effect at 5:00 p.m. Eastern Time on a specified date in the near future.
This strategic decision, approved by stockholders during the recent Annual Meeting, aims to align the company with the Nasdaq Capital Market's minimum bid price requirement. By consolidating shares, Sensei Biotherapeutics is not only preserving its listing status but also enhancing its market viability.
Understanding the Reverse Stock Split
Following the implementation of the reverse stock split, every 20 shares currently held by stockholders will be transformed into a single share. This effectively reduces the total outstanding shares from approximately 25.2 million to around 1.3 million, bringing substantial changes to the company's share structure. The authorized shares will also reduce from 250 million to 12.5 million, reflecting a proactive approach to managing the company’s capital.
For stockholders, this adjustment means that while the number of shares will decrease, the value per share is anticipated to increase proportionately. Importantly, fractional shares will not be issued; instead, stockholders entitled to a fractional share will receive cash payments, ensuring equity is maintained across all shareholders.
Operational Details and Support for Shareholders
The transition to a split-adjusted basis will commence when the markets open shortly after the specified effective date, allowing for a seamless integration for investors. Those holding shares electronically need not take any action, as the share adjustments will happen automatically. For shareholders utilizing brokers or banks, their accounts will reflect the changes without the need for individual requests.
Equiniti Trust Company, LLC has been appointed as both the exchange agent and transfer agent, facilitating this smooth transition process for stockholders. This support ensures that shareholders stay well-informed and comfortable during this period of change.
About Sensei Biotherapeutics
At its core, Sensei Biotherapeutics is committed to transforming cancer treatment through its advanced TMAb™ (Tumor Microenvironment Activated biologics) platform. This cutting-edge technology is designed to develop therapeutics that precisely target and interact with the tumor microenvironment. This means therapies can selectively disable signals that suppress the immune response or activate signals that stimulate it, unleashing the body’s natural defense mechanisms against tumors.
One of Sensei’s flagship products is solnerstotug, a conditionally active antibody aimed at blocking specific checkpoints that hinder T cell activation. This innovation is carefully designed to function at the low pH levels characteristic of the tumor environment, directly addressing the challenges presented in traditional cancer therapies.
Looking Ahead
As Sensei Biotherapeutics approaches this pivotal stage in its corporate journey, there is a sense of optimism surrounding the impact of the reverse stock split on its share price. By complying with Nasdaq's requirements, the company is well-positioned to continue its pioneering work in the biotechnology field. Investors are expected to closely monitor the upcoming changes as the company remains committed to developing life-altering therapeutics for cancer patients.
Frequently Asked Questions
What is the purpose of the reverse stock split by Sensei Biotherapeutics?
The reverse stock split is aimed at meeting Nasdaq's minimum bid price requirement, ensuring the company remains listed on the exchange.
How will the reverse stock split affect current shareholders?
While the number of shares will decrease, the value per share is expected to increase proportionately. Shareholders will receive cash for any fractional shares.
When will the reverse stock split take effect?
The reverse stock split will be effective at 5:00 p.m. Eastern Time on the specified effective date.
Who is the exchange agent for the reverse stock split?
Equiniti Trust Company, LLC is the appointed exchange and transfer agent for managing the reverse stock split process.
What is the key product of Sensei Biotherapeutics?
Sensei Biotherapeutics is known for its product candidate solnerstotug, designed to block specific immunosuppressive signals in the tumor microenvironment.
